Resumen
Este trabalho teve a finalidade de avaliar a eficácia clínica da fluoxetina (F), adjunta a uma dieta de 1 500 Kcal/dia, na redução de parâmetros antropométricos e bioquímicos em mulheres obesas. F (60 mg/dia), foi comparada ao Placebo (P) (n = 10) em 19 mulheres obesas, durante 90 dias de tratamento. O grupo F (n = 9) apresentou uma redução no IMC (-3.64 vs -0.45 kg/m²; p < 0.01) e circunferência abdominal (-12.3 vs -2.9 cm; p < 0.01). Observou-se ainda uma elevação dos níveis séricos de HDL-colesterol (+25.8%; p < 0.01), além de uma redução dos níveis plasmáticos médios de triglicérides (-28.3 % vs +18.7%; p < 0.01). As reações adversas mais comumente reportadas foram insônia, náuseas e sonolência. Concluímos que a fluoxetina, associada a uma dieta apropriada, demonstrou ser um fármaco bem tolerado e eficaz na redução de parâmetros antropométricos e bioquímicos em mulheres obesas.

Palabras clave
fluoxetina, obesidade, terapia farmacológica, reações adversas

Artículo completo
(castellano)
Extensión:  +/-5.18 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Obesity is a chronic condition that has been reaching epidemic proportions worldwide. It is a risk factor for numerous medical disorders and excessive mortality. Long-term treatment, including pharmacotherapy, may be necessary for many obese patients. This study aimed to assess the potential benefits of fluoxetine (F), as an adjunct therapy to a 1 500 Kcal/day diet, in obese women. F (60 mg/day), was compared to placebo (P) in 19 obese females in a 90-day trial. F therapy (n = 9) resulted in a greater mean reduction in body weight (-9.24 vs -1.05 kg; p < 0.01), BMI (-3.64 vs -0.45 kg/m², p < 0.01), and waist circumference (-12.3 vs -2.9 cm, p < 0.01) before and after the treatment, and also when compared with P group (n = 10). There was also an elevation of HDL-cholesterol before and after the treatment (p < 0.01; + 25.8%) and mean triglycerides levels was reduced before and after the treatment (p < 0.01; -28.3%), and also when compared with the P group. The drug was generally well tolerated and side effects most commonly reported were anorexia, insomnia, nausea and somnolence. We concluded that Fluoxetine may provide an effective and well tolerated possibility in reducing risk factors commonly associated with obesity.

Key words
fluoxetine, side effects, pharmacotherapy, obesity